Stromacare Logo

Cancer Immunotherapy through Stroma Modulation

THE TEAM

Pierre-Olivier GOINEAU
Chief Executive Officer
Co-founder

LINKEDIN

Pierre-Olivier is passionate about innovation in the field of health. For more than 20 years, he has accompanied, co-founded and managed numerous companies providing new therapeutic solutions in order to better treat patients. He has succeeded in signing numerous licensing and partnership agreements with major players in the life sciences, and in raising funds from professional investors and public markets.

He was notably co-founder and director of Erytech Pharma, Chairman of Axoltis and Chairman of France Biotech, the French association of innovative companies in the life sciences.Pierre-Olivier holds a Master Degree in Strategy & Finance, and another one in Management of Pharmaceutical Industry from IAE Lyon University.

Ana HENNINO, PhD
Chief Scientific Officer
Co-founder

Ana Hennino is at the origin of the project, she completed her PhD as an ENS student in Immunology at the INSERM in Lyon in 2001. She developed during PhD studies expertise in molecular mechanisms involved in apoptosis in B cell compartment and identified c-FLIP as a key regulator of the apoptosis of B cells in the germinal center.

Through her post-doctoral studies in the field of immunology of allergy she demonstrated an important role of the CD8+ T cell response at the initiation of the skin-allergic immune response. Since 2014, her research in CancerResearch Center Lyon focuses on the regulation of the immune response by the stromal compartment in the context of autoimmunity and cancer.

Prof. Eric RAYMOND, MD, PhD
Interim Chief Medical Officer / Medical Advisor

LINKEDIN

Eric is an expert in early clinical development and helps Stromacare to fine tune its clinical pathway. He is head of medical oncology at Groupe Hospitalier Paris Saint-Joseph since 2016.

He spent all his carrier in oncology department of prestigious hospitals : Lausanne Hospital, Beaujon Paris Hospital, Saint-Louis Paris Hospital, IGR Paris. He is MD and holds a PhD in Molecular Biology from Pierre et Marie Curie Paris University.

Karine Aguerra
Chief Program Director

LINKEDIN

Mrs. Karine Aguerra is Program Director.
Karine has worked for more than 15 years in the field of biotechnology in project management. She oversaw all the coordination of a major program involving the regulatory authorities, and the medical, pharmaceutical, quality control and R&D teams.

She likes to work cross-functionally with teams from different professional cultures, both internally and externally. Her rigor and her ability to gather information, to mobilize stakeholders, to meet deadlines are decisive for StromaCare where she will be in charge of all the management of the development project of our Lead as well as the editorial parts R&D and toxicity of the regulatory files.

Sophie BACHY
Lab Manager

LINKEDIN

Sophie Bachy is a research engineer. She has worked for the past few years in the Inserm laboratory led by Ana Hennino and has carried out a large number of the experiments that make up the POC
.
She has extensive experience in research and development acquired in many companies, for example Valneva.

Pierre-Olivier GOINEAU

Chief Executive Officer Co-founder
LINKEDINORCID

Pierre-Olivier is passionate about innovation in the field of health. For more than 20 years, he has accompanied, co-founded and managed numerous companies providing new therapeutic solutions in order to better treat patients. He has succeeded in signing numerous licensing and partnership agreements with major players in the life sciences, and in raising funds from professional investors and public markets.

He was notably co-founder and director of Erytech Pharma, Chairman of Axoltis and Chairman of France Biotech, the French association of innovative companies in the life sciences.Pierre-Olivier holds a Master Degree in Strategy & Finance, and another one in Management of Pharmaceutical Industry from IAE Lyon University.

Ana HENNINO

PhD Chief Scientific Officer Co-founder
LINKEDINORCID

Ana Hennino is at the origin of the project, she completed her PhD as an ENS student in Immunology at the INSERM in Lyon in 2001. She developed during PhD studies expertise in molecular mechanisms involved in apoptosis in B cell compartment and identified c-FLIP as a key regulator of the apoptosis of B cells in the germinal center.

Through her post-doctoral studies in the field of immunology of allergy she demonstrated an important role of the CD8+ T cell response at the initiation of the skin-allergic immune response. Since 2014, her research in CancerResearch Center Lyon focuses on the regulation of the immune response by the stromal compartment in the context of autoimmunity and cancer.

Karine AGUERRA

Chief Program Director
LINKEDINORCID

Mrs. Karine Aguerra is Program Director.Karine has worked for more than 15 years in the field of biotechnology in project management. She oversaw all the coordination of a major program involving the regulatory authorities, and the medical, pharmaceutical, quality control and R&D teams.

She likes to work cross-functionally with teams from different professional cultures, both internally and externally. Her rigor and her ability to gather information, to mobilize stakeholders, to meet deadlines are decisive for StromaCare where she will be in charge of all the management of the development project of our Lead as well as the editorial parts R&D and toxicity of the regulatory files.

Prof. Eric Raymond , MD, PhD

Medical Advisor
LINKEDINORCID

Eric is an expert in early clinical development and helps Stromacare to fine tune its clinical pathway. He is head of medical oncology at Groupe Hospitalier Paris Saint-Joseph since 2016.

He spent all his carrier in oncology department of prestigious hospitals : Lausanne Hospital, Beaujon Paris Hospital, Saint-Louis Paris Hospital, IGR Paris. He is MD and holds a PhD in Molecular Biology from Pierre et Marie Curie Paris University.

José CORREIA

Chief of Quality Officer
LINKEDINORCID

José has spent the last 25 years in biotech companies working, among others, as Director of Quality Assurance, Director of Nonclinical studies, and Director of Clinical studies. He has also led a project up to Phase 3 clinical trial.

He has a broad experience in biological drugs development, from biomanufacturing to clinical trial operations. In its last position, he has set up and managed the Quality Management System for both internal research activities and for GxP subcontracted activities that has allowed to release more than 10 different Investigational Medicinal Products for clinical trials (Phase 1 to Phase 3).

SCIENTIFIC AND MEDICAL BOARD

Professor Frances BALKWILL

Cancer biologist, PhD Barts Cancer Institute Queen Mary University London
LINKEDIN

Professor Vincenzo BARNABA

Immunologist, MD/PhD Sapienza University Roma , Italy
LINKEDIN

Professor In-San KIM

Cellular biologist, Korean Institute of MD/PhD Science and Technology Seoul, Korea
LINKEDIN

Professor Jean-Yves BLAY

Oncologist, MD, PhD Anticancer Center Léon Bérard, Lyon, France
LINKEDIN

Professor Eric RAYMOND

Oncologist, MD, PhD Paris, France MD, PhD hospital Saint-Joseph Paris France
LINKEDIN

THE strategic comitee

Philippe ARCHINARD

PhD Business Angels representative
LINKEDIN

Isabelle BOU ANTOUN

Kreaxi representative
LINKEDIN

Camille DARCISSAC

Pharm D Turenne Capital representative
LINKEDIN

Yann GODFRIN

PhD Historical shareholders
LINKEDIN

Pierre-Olivier GOINEAU

Strategic Comitee President Co-founder & CEO
LINKEDIN

Ana HENNINO

PhD Co-founder & CSO
LINKEDIN

Stéphane LEGASTELOIS

PhD Historical shareholders
LINKEDIN

Laurent SACCUCCI

Credit Agricole Création
LINKEDIN